Home
/
Industries
/
Pharma & Life Sciences
Pharma, API, Injectables, Biotech & CDMO
Your audit conversations sound defensive.
Your regulator is taking notes.
Yzerly builds the spoken and written communication capability your India-based teams need to hold their own with auditors, global clients, and each other, so a deviation stays a deviation instead of becoming a Warning Letter.
Trusted by
Pharma & Life Sciences leaders
The pain today
Five capability gaps your teams are carrying right now.
01
Spoken proficiency is far below what the work demands.
Result
In one diagnostic across a pharma manufacturer's plants, 98 per cent of the people assessed fell below the spoken benchmark. Instructions get misheard, decisions get delayed, and the same clarification loop repeats across sites.
02
Audit and inspection conversations sound defensive.
Result
When a USFDA or WHO-GMP inspector asks about a deviation, technical staff over-explain or freeze. What should have been a Form 483 observation becomes a Warning Letter, and the site loses months of production while responding.
03
Email loops between corporate and plant go around in circles.
Result
A single question takes fifteen emails to settle when it should have taken five. Batches wait, quality holds go up, and delivery slips on the very clients who have the highest expectations.
04
Project, quality, and regulatory teams talk past each other.
Result
Each function speaks in its own vocabulary. Meetings run long and leave everyone with a different summary. Timelines slip, escalations bounce upward, and the cost of a delayed submission is real.
05
Teams cannot translate technical strength into a commercial story.
Result
Scientists and Business Development teams struggle to convert deep technical credibility into a language a global procurement head can act on. Deals slow down at the negotiation stage, and pricing power erodes.
The pain today
Five capability gaps your teams are carrying right now.
01
Spoken proficiency is far below what the work demands.
Result
In one diagnostic across a pharma manufacturer's plants, 98 per cent of the people assessed fell below the spoken benchmark. Instructions get misheard, decisions get delayed, and the same clarification loop repeats across sites.
02
Audit and inspection conversations sound defensive.
Result
When a USFDA or WHO-GMP inspector asks about a deviation, technical staff over-explain or freeze. What should have been a Form 483 observation becomes a Warning Letter, and the site loses months of production while responding.
03
Email loops between corporate and plant go around in circles.
Result
A single question takes fifteen emails to settle when it should have taken five. Batches wait, quality holds go up, and delivery slips on the very clients who have the highest expectations.
04
Project, quality, and regulatory teams talk past each other.
Result
Each function speaks in its own vocabulary. Meetings run long and leave everyone with a different summary. Timelines slip, escalations bounce upward, and the cost of a delayed submission is real.
05
Teams cannot translate technical strength into a commercial story.
Result
Scientists and Business Development teams struggle to convert deep technical credibility into a language a global procurement head can act on. Deals slow down at the negotiation stage, and pricing power erodes.
Why solve this now
A regulatory event is a communication failure before it is a compliance one.
»
The USFDA publishes every Warning Letter and Form 483 it issues. Indian pharma has been among the largest recipients of Warning Letters against foreign firms in recent years, and each one is a permanent, searchable public record.
»
CDSCO's public alert notifications are indexed and searchable, and every alert is a matter of public record.
Source
»
A regulatory event affects share price, credit rating, and future contract wins. Fixing how your teams explain a deviation costs a fraction of defending one after the fact.
Why solve this now
A regulatory event is a communication failure before it is a compliance one.
»
A regulatory event affects share price, credit rating, and future contract wins. Fixing how your teams explain a deviation costs a fraction of defending one after the fact.
Source
»
How Yzerly approaches it
FGD first. Success charter next. Measured outcome always.
We start with a manager FGD and an employee expectation-setting session. From that we evaluate each participant and create a success charter, specific to your process, your regulator mix, and your client geography. We deliver on-site so the shop-floor context stays real. Sessions are short-format, spaced across weeks, and measured against the success charter, not attendance and not test scores. Facilitators are trained in your terminology before Day 1.
Client Impact
Outcomes we have delivered for Pharma & Life Sciences clients.
50 → 75
%
Client satisfaction across 250 participants at 13 manufacturing sites.
Pharma CDMO, 2023-2026
52 → 67
%
Communication NPS among the CDMO's global customers, a 15-point lift.
Pharma CDMO
15 → 5
%
Email loops between corporate and plant, with email quality up 28 per cent.
Pharma manufacturer
97
%
Of managers reported a marked improvement in their team's confidence, articulation, and client-facing communication.
Pharma CDMO
"
The session was fantastic! All the participants truly enjoyed it from start to finish. The trainer was exceptionally knowledgeable, and their simple and effective way of explaining even complex topics made the session both engaging and easy to follow... Kudos to you both for organizing such a well-structured and impactful session!
Anuj Yagik
Senior HR Executive
See the work
On-site with our Pharma & Life Sciences clients.
On-site session: shop floor, meeting room, or quality lab context.
File: pharma-onsite-training.jpg
30 to 60 second testimonial from a Site Head or Quality Head.
File: pharma-testimonial.mp4
Who we serve in Pharma & Life Sciences
The roles that carry your site and client conversations.
Who we serve in Pharma & Life Sciences
The roles that carry your site and client conversations.
Executive & Management
Chief Managers
General Managers
Deputy General Managers
Senior Managers
Managers
Deputy Managers
Senior Executives
Scientific & Technical
Principal Scientists
Senior Research Scientists
Research Scientists
Senior Research Associates
Lead Analytical Scientists
Analytical Scientists
Specialised & Operational
Regulatory Affairs
EHS Managers
Supply Chain Managers
IT Infrastructure & SAP Support
Quality Control Teams
Production Teams
Documentation Controllers
Plant Manufacturing Personnel
Frequently asked
What Pharma & Life Sciences leaders ask us before we start
Frequently asked
What Pharma & Life Sciences leaders ask us before we start
Our team already knows the science inside out. Why do they need a communication programme for audits?
Auditors are not questioning your technical strength, they are reading how clearly you explain it. That clarity is a skill we can teach, and it is what keeps a Form 483 observation from turning into a Warning Letter.
Do you handle cultural sensitisation for teams working with EU, Japan, and US clients?
Yes. Cultural sensitisation covers the specific nuances of the region your team works with, including familiarising them with the accents they will hear on calls. We have taught the art of persuasion in a multicultural environment, and how to build trust while navigating cultural differences, whether that is pace of speech, use of silence, or how to disagree and escalate.
How do you customise for our regulator mix and product mix?
Before we design anything, we run a manager connect: a focus group with the managers who own the output, so we hear the gap from the people who live with it daily. Alongside that, the diagnostic maps your current audit history, your client geographies, and the proficiency levels of English across your teams. Only then is the design built, customised to your generics-versus-speciality split, your API-versus-formulation mix, and the specific regulators you face.